In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

LeukoSite, Ilex, and Schering sign Campath agreement

Executive Summary

Ilex Oncology (drug development for cancer) and LeukoSite granted exclusive worldwide development and distribution rights, except in Japan and East Asia where they will retain rights, to Schering for Campath, a late-stage humanized monoclonal antibody that LeukoSite originally licensed from BTG PLC. Campath is used in the treatment of chronic lymphocytic leukemia (CLL), the most prevalent form of adult leukemia.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • Marketing (Licensing)

Related Companies